CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18,481 enrolled
Drug / intervention
insulin detemirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00825643
NCT00825643N/ACompleted
CompareCT.gov

A Multicentre, Open Label, Observational 24-week Study to Evaluate Safety of Initiating Insulin Therapy With Levemir® (Insulin Detemir) Once-daily in Oral Antidiabetic Drug-treated Patients With Type 2 Diabetes

Novo Nordisk A/S·observational·Posted Jan 21, 2009·Updated Feb 13, 2017

In Brief

An observational study evaluating insulin detemir for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 18,481 participants across 9 sites in 9 countries.

Detailed Summary

This study is conducted in Europe, North America and Asia. The aim of this observational study is to evaluate the safety and effectiveness while using Levemir® once daily in combination with oral antidiabetic drugs in type 2 diabetics during 24 weeks under normal clinical practice. Data from the NN304-3573 study (NCT00740519) will be pooled with data from this study and reported together in the final study report for this study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesCanada, China, Germany, Israel, Italy, Poland, Portugal, Spain, Turkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 21, 2009
Enrollment StartApr 1, 2008
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.4 years ago

Interventions

insulin detemirdrug

Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation